Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999385 | 1.00 | CHRNA7 (0.64) | CHRNA7CYP1A2CYP2D6CHRM1CHRM2 | |
| SCHEMBL3844303 | 0.87 | CHRNA7 (0.48) | CHRNA7CHRM1CHRM2CHRM3CHRM4 | |
| SCHEMBL999498 | 0.87 | CHRNA7 (0.48) | CHRNA7CHRM1CHRM2CHRM3CHRM4 | |
| SCHEMBL999496 | 0.87 | CHRNA7 (0.48) | CHRNA7CHRM1CHRM2CHRM3CHRM4 | |
| SCHEMBL5402635 | 0.86 | CHRNA7 (0.48) | CHRNA7CHRM1CHRM2CHRM3NTMT1 | |
| SCHEMBL3844040 | 0.86 | LSS (0.51) | CHRNA7CYP1A2CYP2D6CHRM1CHRM2 | |
| SCHEMBL5417567 | 0.86 | CHRNA7 (0.48) | CHRNA7CHRM1CHRM2CHRM3NTMT1 | |
| SCHEMBL1459609 | 0.86 | CHRNA7 (0.51) | CHRNA7CHRM1CHRM2CHRM3CHRM4 | |
| SCHEMBL1459611 | 0.86 | CHRNA7 (0.51) | CHRNA7CHRM1CHRM2CHRM3CHRM4 | |
| SCHEMBL3843580 | 0.86 | CHRNA7 (0.51) | CHRNA7CYP1A2CYP2D6CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480228-B1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2016-11-16 | — | — | EP | claimed |
| US-9012451-B2 | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists | NOVARTIS AG (CH) | 2015-04-21 | — | — | US | claimed |
| EP-1537104-B1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| EP-2931315-B1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828642-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2017-11-28 | — | — | US | disclosed |
| EP-2685977-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | Novartis AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| WO-2013057687-A2 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012127393-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| EP-2480228-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG | 2012-07-05 | — | — | US | disclosed |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | NOVARTIS AG | 2012-06-21 | — | — | US | disclosed |
| EP-2456438-A2 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011036167-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011009890-A2 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CYP1A2 3722/4885CYP2D6 4137/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CYP1A2 3801/4885CYP2D6 4172/4885 |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CYP1A2 3895/4885CYP2D6 4259/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CYP1A2 3801/4885CYP2D6 4172/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CYP1A2 3895/4885CYP2D6 4259/4885 |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | ATXN2, CDR2, ATXN2L | CHRNA7 205/4885CYP1A2 1563/4885CYP2D6 2385/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CYP1A2 3722/4885CYP2D6 4137/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CYP1A2 3895/4885CYP2D6 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.